

From: Vance, John - OWCP  
 To: Rhoads, Carrie - OWCP  
 Cc: Reinhart, David F. - OWCP  
 Subject: Follow-up Board Question  
 Date: Tuesday, November 09, 2021 8:17:09 AM  
 Attachments: image001.png

Carrie,

I have a quick follow-up to the discussion the Board had with this yesterday:

- (26) IARC Group 2A carcinogens should be linked to cancer sites in SEM/SEM should specify IARC and NTP evaluations have been used in addition to HAZ-MAP/Data from IARC and NTP should be sued in addition to HAP-MAP from health effects and linkages for toxic substances to cancers;

The Board mentions two toxins (Aldrin & Dieldrin) when discussing the breast cancer health effect. Both are listed in SEM as occupational toxins, but it is unclear what we are to do about the reference to Dieldrin being a metabolite of Aldrin. It would seem that under the context of the recommendation – occupational exposure to Aldrin causes the human body to produce Dieldrin. The reference from the Board then connects Dieldrin to breast cancer. The question is what toxin from an occupational exposure connects to breast cancer. Is an occupational exposure to Dieldrin the same as having the body produce it from Aldrin intake? We also do not know what the reference to “inadequate evidence for Aldrin” means. From Table 1, is breast cancer an accepted health effect from occupational exposure to one or both: Aldrin/Dieldrin?

Per the Board’s response to this questions, DOL is going to add both toxins as a health effect for breast cancer. However, two questions have surfaced that I am hoping that the Board can address quickly today, as I think they may be returning to the IARC 2A discussion:

1. Should SEM differentiate male vs. female breast cancer given they have separate ICD 9/10 codes?

Female Breast Cancer 174.9/C50.909  
 Male Breast Cancer 175.9/C50.929

2. However, the cancers are listed in SEM – should Breast Cancer (Female), Breast Cancer (Male), or both be linked to Aldrin and Dieldrin?

Here is the relevant section of the Table the Board submitted to DOL – for reference:

2A Carcinogen cited by ABTSWH*	Existing Appearance in SEM	Proposed Appearance in SEM	Associated Cancers cited by ABTSWH*	Proposed Disease 1 to be added to SEM	Proposed Disease 2 to be added to SEM	Proposed Disease 3 to be added to SEM
Aldrin and its metabolite dieldrin [Inadequate evidence for aldrin, but limited evidence for its metabolite dieldrin]	Aldrin	Aldrin (no change). The ABTSWH recommendation is unclear. Need decision from DOL: Is Cancer of the Breast to be added as a new health effect of Aldrin and Dieldrin in SEM, or just Dieldrin?	Cancer of the Breast	Cancer of the breast - Not in SEM or Haz-Map. Need DOL decision on disease title, which ICD-9/10 Diagnosis Code(s) to apply, and applicability to females, males, or both.	na	na
Aldrin and its metabolite dieldrin [Inadequate evidence for aldrin, but limited evidence for its metabolite dieldrin]	Dieldrin	Aldrin (no change). The ABTSWH recommendation is unclear. Need decision from DOL: Is Cancer of the Breast to be added as a new health effect of Aldrin and Dieldrin in SEM, or just Dieldrin?	Cancer of the Breast	Cancer of the breast - Not in SEM or Haz-Map. Need DOL decision on disease title, which ICD-9/10 Diagnosis Code(s) to apply, and applicability to females, males, or both.	na	na
Silicon Carbide “Whiskers”	Not in SEM	Silicon carbide whiskers (new primary substance)	Lung Cancer	Lung Cancer (already in SEM) ICD-9 Code: 162 ICD-10 Code: C33	na	na

\*From Advisory Board on Toxic Substances and Worker Health (ABTSWH) Table 1.